╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╡
│ No prior treatment with Ventavis or other active   │ No prior treatment with Ventavis or other active  │
│ treatments for primary pulmonary hypertension      │ treatments for primary pulmonary hypertension     │
│ within 6 weeks of date of study inclusion (unless  │ within 6 weeks of date of study inclusion (unless │
│ otherwise advised by Bayer Schering Pharma)        │ otherwise advised by Bayer Schering Pharma)       │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ The treating physician has chosen Ventavis as a    │ The treating physician has chosen Ventavis as a   │
│ suitable long-term treatment for the patient       │ suitable long-term treatment for the patient      │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Patient with primary pulmonary hypertension (i.e.  │ Patient with primary pulmonary hypertension (i.e. │
│ Idiopathic Pulmonary Arterial Hypertension or      │ Idiopathic Pulmonary Arterial Hypertension or     │
│ Familial Pulmonary Arterial Hypertension) and      │ Familial Pulmonary Arterial Hypertension) and     │
│ classified as NYHA functional class III (NYHA =    │ classified as NYHA functional class III (NYHA =   │
│ New York Heart Association)                        │ New York Heart Association)                       │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                  │ No Match                                          │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Other contraindications for Ventavis treatment (as │ No Match                                          │
│ listed in the current Ventavis Summary of Product  │                                                   │
│ Characteristics and patient package insert)        │                                                   │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Any condition that prevents participation in the   │ Any condition that prevents participation in the  │
│ study, including pregnancy                         │ study, including pregnancy and other              │
│                                                    │ contraindications for Ventavis treatment (as      │
│                                                    │ listed in the current Ventavis Summary of Product │
│                                                    │ Characteristics and patient package insert)       │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╛